D3 Bio Inc., a biotechnology company, has announced promising first-line clinical data for its next-generation KRAS G12C inhibitor, elisrasib, in treating non-small cell lung cancer (NSCLC). The data, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, highlights the efficacy of elisrasib both as a monotherapy and in combination with pembrolizumab.

Elisrasib Monotherapy Results

In a study involving 43 patients with untreated KRAS G12C mutation-positive NSCLC, elisrasib monotherapy achieved an overall response rate (ORR) of 78.0% across all PD-L1 expression levels. The median progression-free survival (PFS) was 12.4 months, and the 12-month overall survival rate was 90.0%. The treatment was well tolerated, with only 7% of patients experiencing severe treatment-related adverse events (TRAEs).

Combination Therapy with Pembrolizumab

When combined with pembrolizumab, elisrasib showed an ORR of 81.3% in 48 efficacy-evaluable patients. The combination therapy demonstrated a favorable safety profile, with no new safety concerns identified. The 12-month PFS rate was 53.7%, and the 12-month overall survival rate was 88.8%.

These results suggest that elisrasib, both alone and in combination with pembrolizumab, could offer a promising new treatment option for patients with KRAS G12C-mutant NSCLC. The study’s lead presenter, Prof. Shun Lu, emphasized the strong antitumor activity and favorable tolerability of elisrasib, marking it as a potential breakthrough in treating this challenging cancer type.

D3 Bio plans to continue evaluating elisrasib in Phase 3 studies to further establish its efficacy and safety. The company’s commitment to developing innovative oncology therapeutics is evident in its ongoing research efforts.

Original reporting: KTBS 3 (Shreveport) — read the source article.